Recognizing features that are dissimilar in male and female breast cancer: Expression of p21Waf1 and p27Kip1 using an immunohistochemical assay

Annals of Oncology

Volumn 13, Issue 6, 2002, Pages 895-902

  Curigliano, G ^a,b   Colleoni, M ^a   Renne, G ^c   Mazzarol, G ^c   Gennari, R ^d   Peruzzotti, G ^a   de Braud, F ^a,b   Robertson, C ^e   Maiorano, E ^f   Veronesi, P ^d   Nole, F ^a   Mandala, M ^a   Ferreti, G ^a   Viale, G ^c,g   Goldhirsch, A ^a  

^a Medical Oncology Division   (Italy)

^b Department of Medicine   (Italy)

^c Laboratory Medicine   (Italy)

^d Divisions of Senology   (Italy)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^f UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

Author keywords

Male breast cancer; p21; p27

Indexed keywords

ANDROGEN RECEPTOR; CYCLIN DEPENDENT KINASE; HORMONE RECEPTOR; KI 67 ANTIGEN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53; SEX HORMONE; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LABELING INDEX; MAJOR CLINICAL STUDY; MALE; MALE BREAST; MOLECULAR BIOLOGY; ONCOGENE C ERB; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SEX DIFFERENCE; STATISTICAL ANALYSIS; BREAST TUMOR; COMPARATIVE STUDY; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PATHOLOGY; PROBABILITY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL;

ADULT; AGED; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CELL CYCLE PROTEINS; COMPARATIVE STUDY; CYCLIN-DEPENDENT KINASES; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; LINEAR MODELS; MALE; MIDDLE AGE; ONCOGENE PROTEIN P21(RAS); PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEX FACTORS; TUMOR SUPPRESSOR PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HUMANS; MIDDLE AGED;

EID: 0035990089     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf166     Document Type: Article

References (35)

1. The regulation of p53 function: Steiner Award lecture
2. Molecular epidemiology
3. Molecular control of growth arrest and apoptosis: p53-dependent and independent pathways
4. Prognostic and predictive value of p53 and p21 in breast cancer
5. waf1 expression and endocrine response in breast cancer
6. Prognostic value of p21 and p53 expression in breast carcinoma: An immunohistochemical study in 261 patients with long term follow up
7. The p21 (Cip1) and p27 (Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts
8. Multiple functions of p27 (Kip1) and its alterations in tumor cells: A review
9. Kip1, a cyclin dependent kinase inhibitor and a potential mediator of extra-cellular antimitogenic signals
10. Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation
11. Promoting apoptosis: A novel activity associated with the cyclin-dependent kinase inhibitor p27
12. kip1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma
13. Differentiation of neuroblastoma enhances Bcl-2 expression and induces alterations of apoptosis and drug resistance
14. Bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer
15. Tyrosine kinase receptor with extensive homology to EGF receptors shares chromosomal location with neu oncogene
16. HER2. A 'predictive factor' ready to use in the daily management of breast cancer patients?
17. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
18. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen-receptor positive, node-positive breast cancer
19. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival
20. Prognostic parameters in male breast cancer
21. Male breast cancer: Clinico-pathological features, immunocytochemical characteristics and prognosis
22. Molecular markers in male breast carcinoma
23. Male breast cancer: A review of the literature
24. Male breast carcinoma: A review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996
25. Prognostic variables in male breast cancer
26. Histological typing of breast tumors
27. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow up
28. Decreased levels of the cell-cycle inhibitor p27 protein: Prognostic implications in primary breast cancer
29. Expression of cell-cycle regulators p27 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients
30. Down regulation of p21 or p27 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells
31. Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X, without alteration of p53 protein levels
32. Estrogen receptors in male breast cancer
33. Treatment of early breast cancer: Worldwide evidence in 1985-1990. A systematic overview of all avalaible randomized trials in early breast cancer of adjuvant endocrine and cytoxic therapy
34. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer